See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $297B | 4.6x | 10.0x | |
| $196B | 3.2x | 7.9x | |
| $128B | 2.4x | 8.0x | |
| $123B | 2.8x | 8.2x | |
| $69.8B | 4.2x | 12.5x | |
| $58.4B | 6.7x | 21.7x | |
| $13.4B | 7.0x | -4.2x | |
| $11.5B | 3.7x | -9.3x | |
| $7.6B | 3.7x | -39.8x | |
| $7.2B | 7.3x | 23.7x | |
| $7.1B | 24.1x | 568.4x | |
| $6.4B | 58.0x | n/a | |
| $5.4B | n/a | -6.4x | |
| $4.2B | 10.0x | 30.6x | |
| $3.6B | 5.3x | 14.3x | |
| $3.1B | n/a | n/a | |
| $2.7B | 7.5x | 26.1x | |
| $2.7B | n/a | n/a | |
| $2.5B | 6.1x | 22.8x | |
| $2.4B | 314.6x | -11.6x | |
| $2.3B | 5.2x | -83.2x | |
| $2.3B | n/a | n/a | |
| $1.9B | 2.0x | 5.6x | |
| $1.9B | 7.6x | -5.2x | |
| $1.7B | n/a | n/a | |
| $1.6B | 6.5x | 280.7x | |
| $1.6B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.4B | 4.1x | 57.0x | |
| $1.3B | 491.1x | -8.5x | |
| $1.2B | 6.6x | 18.0x | |
| $1.2B | n/a | n/a | |
| $1.2B | n/a | n/a | |
| $1.1B | 5.3x | -39.9x | |
| $1.1B | 12.6x | -31.8x | |
| $1.1B | 404.4x | -4.0x | |
| $1.0B | n/a | n/a | |
| $969M | 31.5x | -26.1x | |
| $934M | 5.9x | 12.5x | |
| $927M | n/a | -12.0x | |
| $926M | 0.9x | 2.4x | |
| $859M | 4.3x | -16.6x | |
| $836M | n/a | n/a | |
| $828M | 10.0x | -76.2x | |
| $784M | 16.7x | -4.0x | |
| $727M | 3.9x | n/a | |
| $630M | 30.3x | -1.3x | |
| $581M | 13.5x | -3.9x | |
| $542M | n/a | n/a | |
| $536M | n/a | n/a | |
| $525M | n/a | n/a | |
| $521M | n/a | n/a | |
| $508M | n/a | n/a | |
| $475M | 84.8x | n/a | |
| $456M | n/a | n/a | |
| $419M | 2.3x | 9.4x | |
| $413M | n/a | n/a | |
| $408M | 8.1x | -7.3x | |
| $347M | n/a | n/a | |
| $311M | n/a | -1.8x | |
| $308M | 28.1x | -7.8x | |
| $307M | n/a | n/a | |
| $303M | 241.1x | -1.0x | |
| $300M | n/a | n/a | |
| $294M | n/a | -11.4x | |
| $276M | n/a | -9.9x | |
| $240M | n/a | -5.2x | |
| $238M | 131143.9x | -1.2x | |
| $235M | 10422.9x | -1.3x | |
| $223M | n/a | n/a | |
| $198M | 68.8x | -10.3x | |
| $185M | 5.6x | n/a | |
| $162M | 135.0x | -3.4x | |
| $151M | n/a | n/a | |
| $145M | 1.1x | n/a | |
| $132M | n/a | n/a | |
| $127M | n/a | n/a | |
| $123M | 2.4x | -41.4x | |
| $119M | n/a | n/a | |
| $113M | n/a | -0.6x | |
| $110M | 2.5x | -0.6x | |
| $106M | n/a | n/a | |
| $103M | n/a | n/a | |
| $102M | n/a | n/a | |
| $101M | n/a | n/a | |
| $97.6M | n/a | -3.9x | |
| $95.3M | 13.1x | n/a | |
| $86.5M | n/a | n/a | |
| $82.1M | n/a | n/a | |
| $75.8M | n/a | n/a | |
| $74.1M | 14.8x | n/a | |
| $70.5M | 798.3x | n/a | |
| $69.6M | 11.8x | n/a | |
| $63.0M | 0.8x | -0.2x | |
| $54.6M | 16.8x | -1.5x | |
| $53.3M | n/a | n/a | |
| $46.7M | n/a | n/a | |
| $46.4M | 45.0x | -1.6x | |
| $46.0M | 23.4x | n/a | |
| $45.0M | n/a | n/a | |
| $44.4M | n/a | n/a | |
| $43.8M | n/a | n/a | |
| $42.1M | n/a | n/a | |
| $41.1M | 0.3x | 1.1x | |
| $40.7M | n/a | n/a | |
| $37.3M | n/a | -1.1x | |
| $30.8M | 2.9x | n/a | |
| $28.6M | n/a | n/a | |
| $18.0M | 2.5x | n/a | |
| $15.8M | n/a | n/a | |
| $15.4M | 230.3x | n/a | |
| $15.3M | n/a | n/a | |
| $13.3M | n/a | n/a | |
| $11.8M | 8.2x | -0.7x | |
| $9.4M | 348.8x | n/a | |
| $9.3M | 3.0x | -0.6x | |
| $8.3M | n/a | -0.1x | |
| $6.4M | 0.1x | n/a | |
| $3.7M | n/a | -0.1x | |
| $3.4M | 1.4x | n/a | |
| $2.9M | 0.5x | n/a | |
| -$0.1M | -0.0x | 0.0x | |
| -$11.2M | -3.9x | n/a | |
| -$15.8M | n/a | n/a | |
| -$30.7M | -2.9x | 0.2x | |
| -$33.3M | n/a | n/a | |
| -$48.7M | n/a | n/a | |
| -$56.7M | n/a | n/a | |
| -$85.9M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies